Q BioMed Inc. Announces Mannin Research Accepted Into Johnson & Johnson Innovation, JLABS @ Toronto

NEW YORK, February 2, 2017  — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to announce that Mannin Research, its research partner for the development of a novel pharmaceutical eye-drop to treat Primary Open-Angle Glaucoma utilizing the Tie2 Mechanism of Action, has been accepted into Johnson & Johnson Innovation, JLABS @ Toronto. […]

Read More

Q BIOMED INC. TECHNOLOGY PARTNER MANNIN RESEARCH INC. TO PARTICIPATE IN A WEBCAST ON INNOVATING FOR OPHTHALMIC DISEASES

Q BIOMED INC. Technology Partner Mannin Research Inc. to participate in a webcast on innovating for ophthalmic diseases Webcast, part of the Nature.Com BioPharma Dealmakers series, is scheduled for 10:00 am ET on October 20th. NEW YORK, October 19, 2016 — Q BioMed Inc. (OTCQB: QBIO), technology partner Mannin Research Inc. will present in a […]

Read More

Q BIOMED DRUG DEVELOPMENT PARTNER TO ATTEND EANM 2016 in BARCELONA, SPAIN October 15-19 2016

Q BIOMED DRUG DEVELOPMENT PARTNER TO ATTEND EANM 2016 in BARCELONA, SPAIN October 15-19 2016 Annual European Association Nuclear Medicine Congress Most Valuable Meeting World Wide NEW YORK, October 18, 2016 — Q BioMed Inc. (OTCQB: QBIO), drug development partner will attend the European Association of Nuclear Medicine (EANM) meeting in Barcelona, Spain. With more […]

Read More

Q BIOMED PARTNER MANNIN RESEARCH EXECUTIVES ATTENDING OIS@AAO 2016 & AAO

Q BIOMED PARTNER MANNIN RESEARCH EXECUTIVES ATTENDING OIS@AAO 2016 & AAO Ophthalmology Summits Attract Broad Range of Industry Professionals NEW YORK, October 13, 2016 — Q BioMed Inc. (OTCQB: QBIO), technology partner Mannin Research Inc will participate at the the Ophthalmology Innovation Summit  and the American Academy of Ophthalmology Annual Meeting in Chicago IL. Mannin […]

Read More

Q BIOMED CLOSES LICENSING AGREEMENT FOR FDA APPROVED DRUG

Q BIOMED CLOSES LICENSING AGREEMENT FOR FDA APPROVED DRUG       Cancer palliation drug expected to start generating revenue in less than 12 months NEW YORK, September 7, 2016 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to announce the closing of an exclusive license and option agreement for a FDA approved […]

Read More

Q BIOMED PROVIDES UPDATE ON CORPORATE DEVELOPMENTS

Q BIOMED PROVIDES UPDATE ON CORPORATE DEVELOPMENTS Media Alert: CEO Interviewed on ‘The Stock Radio’ NEW YORK, September 1, 2016 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to report on its asset acquisition and an update on corporate development. While the summer months have been typically slow, we have made […]

Read More
Social media & sharing icons powered by UltimatelySocial